Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas
NCT00220285Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Bayer. Primary endpoints: Best Overall Response Rate at 13 weeks and Incidence of Critical Toxicity. Started Aug 2004; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00220285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220285.